Agios Got the Record Quarter It Wanted — and the REMS Question It Kept Saying It Wouldn't Get
A $55.4M quarter and $907M of cash, undercut by a three-month PDUFA push that lands squarely on the liver-safety risk management spent four quarters arguing was unlikely to apply.
AGIO · Earnings Call · 2026-11-05
Record revenue, and a clock reset
Agios delivered the best commercial quarter in its history: $55.4M of total net revenue, $48.7M of it in the U.S., against $12.9M in the year-ago quarter. The CEO framed the scale plainly — “in a single quarter, we generated more total revenue than we did in all of 2025” — Brian Goff, Chief Executive Officer · 2026-11-05. The company ended the period with $907M in cash and marketable securities, and the revenue line confirms the inflection in the reported financials: total revenue stepped to $45M in the June quarter, up 259% year over year and 116% sequentially, before the September quarter added another leg.
Then came the thing that actually moved the narrative. On October 9 the FDA asked for more information to decide whether a risk evaluation and mitigation strategy would be needed for mitapivat in sickle cell disease. Agios answered within ten days with roughly nine months of additional RISE UP open-label safety data. The agency classified the response as a major amendment.
The FDA classified our response as a major amendment, which procedurally extends the review timeline by 3 months to February 1, 2027.
That is the whole story in one paragraph: a launch-ready commercial machine, a $907M balance sheet, a February 2027 date instead of November 2026 — and a delay caused by precisely the risk the company had spent four consecutive quarters telling investors probably would not apply to sickle cell. The new keyword in this quarter's deck is potential REMS, which lands in the top five themes for the first time and displaces the confident framing that used to sit there.
The prior confidence, on the record
Read the earlier calls and the shift is not subtle. In July, with the filing on track, the chief medical officer was explicit: “We did not have the hepatocellular injury observed in the sickle cell disease patients. So therefore, it may not warrant the REMS.” — Sarah Gheuens, Chief Medical Officer · 2026-07-30 Go back further, to February, and the going-in position was firmer still — the company would “propose something more like the pyruvate kinase deficiency path” — Sarah Gheuens, Senior Vice President, Clinical Development and Medical Affairs · 2026-02-12, i.e. no REMS at all. And in October 2025, when the thalassemia REMS was the live issue: “the REMS request has been specific to thalassemia” — Brian Goff, Chief Executive Officer · 2025-10-30.
This quarter, the language is careful and conditional: “we are in negotiations with the FDA for label which includes elements of potential REMS, and that is really all that we can comment on at this point in time” — Sarah Gheuens, Chief Medical Officer · 2026-11-05. Nothing here is a lie — the company never promised no REMS, only that the data pointed that way. But the commercial messaging has moved from "probably not needed" to "launch ready in any scenario," and investors are being asked to absorb a three-month slip on the largest addressable indication in the franchise. The commercial chief's framing — “a change in timing and not a change in the commercial opportunity” — Tsveta Milanova, Chief Commercial Officer · 2026-11-05 — is the right argument to make, and also the one every delayed launch makes.
The launch underneath is genuinely good
The thalassemia rollout deserves credit rather than collateral skepticism. Agios added 177 start forms from REMS-certified physicians in the quarter, bringing the cumulative total to 619, or roughly 15% of a ~4,000-patient target launch population three quarters in. Persistency sits at approximately 75% of patients still on therapy at about six months, payer policies cover about 75% of lives with no burden restrictions, and a first direct-to-consumer campaign lifted patient-site engagement 65%. Ex-U.S. revenue rose 74% sequentially on European early access.
Management also confirmed what the keyword decay was already whispering: this is the last quarter of start-form reporting. The vocabulary that taught investors to track this launch — treatment initiation, non-transfusion penetration, hemoglobin responders — is being retired from the disclosure set, and it shows up as the largest negative momentum shifts in the company's keyword history this quarter. That is defensible (revenue is the better metric) and also convenient (revenue hides the funnel).
Rightsizing, and the option value nobody is paying for
The cost story is real. R&D headcount comes down more than 35% — over 100 roles — through 2026, with an ~$11M one-time charge in Q4, part of a headcount reduction program whose savings land in 2027 and frame a 2028 non-GAAP profitability target. Even so, the spending base remains heavy against the new revenue: R&D of $101M ran at more than double the quarter's revenue in the June period, before the cevidoplenib licensing charge annualized out of the comparison. Leverage is a non-issue: liabilities at just 7.4% of assets.
What the market is not paying for is the pipeline reset. Polycythemia Vera is now the single highest-momentum theme in Agios' keyword set, up from a mid-pack mention two quarters ago, on the strength of AG-236: a single dose raised hepcidin by up to 24 micrograms per liter at day 29, effects on iron, transferrin saturation, hemoglobin and hematocrit sustained through month six, all adverse events Grade 1 or 2, and a pharmacokinetic profile supporting every-six-month dosing ahead of a Phase 2/3 start by year-end. Behind it, cevidoplenib in immune thrombocytopenia targets a Phase 3 in the first half of 2028, and AG 181 in PKU delivers proof-of-mechanism data before year-end — with the CEO openly holding out the option of monetizing it.
The tape has already voted, and not kindly. Agios is down 23.8% over 90 days and 35.8% from its July 7 peak of $44.01, leaving a $1.68B market cap against $907M of cash — roughly $775M of enterprise value for a business annualizing above $200M of revenue. Price-to-revenue of 22.5x is down 52% year over year. And the broader market's thematic energy is elsewhere entirely: the global momentum lists are dominated by AI data centers names unwinding, with dozens of decliners clustered under that single theme. Rare hematology appears nowhere in the market-wide advance or decline tables — this is a purely idiosyncratic story.
The February 1, 2027 date is now the entire investment case. Everything between here and there — the December 14 ASH investor event with the RISE UP open-label durability and the kidney and cardiac post-hoc data, the AG-236 six-month readout, the AG-181 PKU proof of mechanism — is supporting evidence for a decision that only the FDA can make. The quarter proved Agios can sell. The delay asks whether it can sell the thing that matters most.